Moxflo Ophthalmic Solution 0.5%

Moxflo Ophthalmic Solution by Ad-din Pharmaceuticals Ltd is a potent antibacterial eye drop containing 0.5% Moxifloxacin Hydrochloride. Designed to treat bacterial conjunctivitis, it targets gram-positive, gram-negative, and Chlamydia trachomatis infections. Priced at ৳160.00 per unit, this ophthalmic solution requires storage below 25°C and protection from light.

The drug inhibits bacterial DNA gyrase (Topoisomerase II) and Topoisomerase IV, disrupting DNA replication. Clinical studies show efficacy against Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. Patients typically apply one drop thrice daily for seven days. Ointment formulations may follow a tapered dosage under medical supervision.

Common ocular side effects include conjunctival hyperemia (1-6% incidence) and dry eyes. Systemic reactions like rhinitis or pharyngitis occur in ≤4% cases. No significant drug interactions with CYP450-metabolized medications have been reported. Use cautiously during pregnancy/lactation due to limited safety data.

Drops: 1 drop in affected eye(s) 3 times daily for 7 days. Ointment: Apply 3 times daily for first 2 days, then twice daily for next 5 days. Wash hands before use; avoid contaminating dropper tip.

The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1-6% of patients. Nonocular adverse events reported at a rate of 1-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.

Pregnancy safety unknown; use only if benefits outweigh risks. Avoid during lactation due to potential secretion in breast milk.

Prolonged use may cause superinfections. Avoid contact lenses during treatment. Keep eyes closed for 15 minutes after application. Regular ocular monitoring recommended.

Pediatric and geriatric dosing data limited. No specific dosage adjustments needed for renal/hepatic impairment, but monitor closely.